It's Tuesday, November 1st, welcome to market foolery.

I'm Chris Hill joining me in studio today for Motley Full Funds, Bill Barker, and from

Motley Full Options, and pro-Canada, the man from the Great White North himself, Jim Gillies.

Greetings and salutations.

Good to see you.

Thanks for once again braving border security.

It was a very simple process today. I'm not sure they were awake.

Wow! We let you in our country and already you're taking shots at our border security?

Well, you know, they were very nice.

He kind of grunted at me, looked at my passport and said kept going.

Usually I expect a little more scrutiny, a little more pain.

I can see that though.

I can see that, I can see that.

I wasn't paying attention. Did you introduce me? Jim. Yeah. I'm going back to not paying attention. That's probably just as well. It is earning season, but that doesn't mean that the news fairy isn't still hard at work.

So we're going to get to a couple of newspaper stocks that are going in opposite directions,

but let's start with, in honor of Jim Gillies, as though this were timed,

Valient Pharmaceuticals, once upon a time, the largest public company in Canada,

which as you pointed out on a previous episode of Market Foolery. That's kind of the as soon as you hear that. That's the death nail for any public company in Canada when you get that's not a bank. That's not a bank. If you're the number one you're the biggest public company it's time to

short that stock. Titles previously held by Nortel, Research and Motion in Briex.

And who is it now? It's back to being Royal Bank of Canada.

Valient Pharmaceuticals.

Former CEO Michael Pearson and former CFO Howard Schiller

...